Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04, 2020, there have bee
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North American Exhibition hel
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new drug for insomnia, i
On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patients with locally adva
The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!
On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the European Commission (EC) h
On March 17th, the State Council's joint prevention and control mechanism held a press conference on the latest rese
2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibitor Nurtec (rimegepant
Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide secreted by the hypo
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related peptide (CGRP) receptor a
Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies that explore